newsfilter
← Latest News
Business Wire·

Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers

Initiated Single-Ascending Dose (SAD) Phase 1 clinical study evaluating LP659 Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative